Phase I
Shares of the company stock plunged in premarket trading after Surface Oncology announced it was scaling back its lead program.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
VAXIMM AG, announced that the first patient has been dosed in a Phase I/II trial evaluating VXM01 oral immunotherapy in combination with avelumab*, a human anti-PD-L1 antibody, for the treatment of glioblastoma.
Earlier this week, the U.S. Food and Drug Administration cleared the company’s Investigational New Drug Application to allow the company to initiate clinical studies with Xeno-Skin, a product designed to provide help for patients who have suffered from significant burns.
Shares of New Jersey-based Advaxis have plunged more than 28 percent in premarket trading after the company quietly disclosed that Amgen terminated its collaboration on an immuno-oncology program. The deal between the two companies was first inked in 2016 and had a value of up to $540 million.
Days after Axovant announced an end to focusing on its legacy small molecule portfolio in favor of gene therapies, the company announced it has licensed worldwide rights to two gene therapy programs from the University of Massachusetts School of Medicine.
Although every year, big biopharma companies give up on some programs, 2018 seems like it has been marked by unusually extensive program abandonment.
White Americans make up the vast majority of clinical trial participants, despite evidence that some cancers affect minority populations in greater numbers.
Positive interim analysis demonstrated proof-of-biology and proof-of-concept for BIIB067
ADCT-402 (loncastuximab tesirine) continues to demonstrate acceptable safety profile and anti-tumor activity in patients with relapsed or refractory diffuse large B-cell lymphoma; data from 183-patient study supports continued evaluation in ongoing pivotal Phase II trial
PRESS RELEASES